In a 41-year-old man with low testosterone (~80 ng/dL) and markedly elevated luteinizing hormone (~15 IU/L) and follicle‑stimulating hormone (~20 IU/L), what is the recommended treatment?

Primary Testicular Failure Requiring Testosterone Replacement Therapy

This 41-year-old man has primary hypogonadism (testicular failure) confirmed by low testosterone (80 ng/dL) with elevated LH (15 IU/L) and FSH (~20 IU/L), and he requires testosterone replacement therapy. 1

Understanding the Diagnosis

The hormonal pattern is diagnostic:

• Testosterone of 80 ng/dL is severely low (normal range typically 300-1000 ng/dL)
• Elevated LH and FSH indicate primary testicular failure - the pituitary is appropriately trying to stimulate the failing testes by producing more gonadotropins 2, 1
• This is "decompensated primary testicular failure" where the testes cannot respond to hormonal signals 2

This differs fundamentally from secondary (central) hypogonadism where both testosterone AND gonadotropins would be low. The elevated gonadotropins confirm the problem originates in the testes themselves, not the brain.

Why Testosterone Therapy is Essential

Testosterone replacement is unequivocally indicated for symptomatic men with primary hypogonadism, regardless of age. 1, 3 The Endocrine Society guidelines explicitly state that men with low testosterone and elevated LH require testosterone replacement therapy 2.

Without treatment, this patient faces:

• Sexual dysfunction (decreased libido and erectile capacity)
• Osteoporosis and fracture risk
• Anemia
• Muscle weakness and sarcopenia
• Depression and fatigue
• Metabolic complications 2

Pre-Treatment Evaluation Required

Before initiating therapy, assess for contraindications 1:

Absolute contraindications:

• Prostate or breast cancer
• PSA >4 ng/mL (or >3 ng/mL with high prostate cancer risk)
• Palpable prostate nodule or induration
• Hematocrit >54%
• Severe untreated obstructive sleep apnea
• Uncontrolled heart failure
• Recent MI or stroke (within 6 months)
• Thrombophilia

Baseline testing:

• Digital rectal exam and PSA
• Complete blood count (hematocrit)
• Lipid panel
• Consider bone density if osteoporosis suspected 4

Treatment Recommendations

Testosterone Formulation Selection

Target testosterone levels in the mid-normal range (450-600 ng/dL). 1, 5

Preferred options 6, 1:

1. Intramuscular testosterone (enanthate or cypionate):

   • 75-100 mg weekly, or 150-200 mg every 2 weeks
   • Most cost-effective option 7
   • Target levels 400-700 ng/dL one week post-injection 6

2. Transdermal gel (1%):

   • 5-10 g applied daily to non-genital skin
   • More stable levels, but higher cost
   • Critical safety warning: Must cover application site with clothing and wash hands; can transfer to women/children through skin contact 6, 4

3. Testosterone patches:

   • 5 mg applied nightly to back, thigh, or upper arm
   • Watch for skin irritation 6, 4

4. Buccal testosterone:

   • 30 mg every 12 hours
   • Monitor for gum irritation 6, 4

The ACP guidelines suggest intramuscular formulations over transdermal when costs are a consideration, as clinical effectiveness and harms are similar 7.

Monitoring Protocol

Initial monitoring (first year) 6, 4, 1:

At 3-6 months:

• Assess symptom response (sexual function, energy, mood)
• Measure testosterone level (aim mid-normal range)
• Check hematocrit (stop if >54%)
• PSA and digital rectal exam
• Evaluate formulation-specific adverse effects

Then annually:

• Same parameters as 3-6 month visit
• Consider bone density at 1-2 years if osteoporosis present 4

Urological consultation required if 6, 4, 1:

• PSA >4.0 ng/mL
• PSA increase >1.4 ng/mL in any 12-month period
• PSA velocity >0.4 ng/mL/year (after 6 months baseline)
• Abnormal digital rectal exam
• Severe lower urinary tract symptoms (AUA/IPSS score >19)

Critical Fertility Consideration

This patient will remain permanently infertile with testosterone therapy alone. 1 Testosterone suppresses the HPG axis, further reducing any residual spermatogenesis.

If fertility is desired now or in the future:

• Testosterone therapy is contraindicated 1
• Refer to reproductive endocrinology for gonadotropin therapy (hCG + FSH) 8
• Consider sperm banking before starting testosterone

Since he has primary testicular failure with already elevated FSH/LH, fertility potential may be severely limited regardless, but this must be explicitly discussed.

Common Pitfalls to Avoid

1. Do not recheck LH/FSH after diagnosis - they will remain elevated and provide no additional management information
2. Do not use calculated free testosterone for monitoring - total testosterone suffices 3
3. Do not stop therapy for hematocrit 50-54% - only stop if >54%, then restart at lower dose after normalization 6, 4
4. Do not forget to counsel about gel transfer risk - this is a serious safety issue for household contacts 6, 4
5. Do not treat without confirming low testosterone on two separate morning samples - though with this degree of elevation in gonadotropins, the diagnosis is secure 1

Expected Outcomes

With appropriate therapy, expect improvements in 6, 5:

• Sexual function and libido (within 3-6 months)
• Bone mineral density (12-24 months)
• Body composition (reduced fat, increased lean mass)
• Mood and energy
• Metabolic parameters

The 2020 ACP guidelines note that testosterone improves sexual function in men with documented hypogonadism, though evidence for other outcomes like energy and cognition is less robust 7. However, those guidelines focused on age-related hypogonadism; this patient has pathological primary hypogonadism where benefits clearly outweigh risks 3.